Esrd clinical trials

Explore recruiting esrd clinical trials.

Recruiting esrd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Esrd trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF MIGALASTAT HCL IN SUBJECTS WITH FABRY DISEASE AND AMENABLE GLA VARIANTS AND SEVERE RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE TREATED WITH HEMODIALYSIS

Spain, France, Portugal

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria

Slovakia, Poland, Italy, Germany, Austria, Sweden +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, randomized, open-label, clinical trial

France

Phase III and phase IV (Integrated) EU CTIS Study details

Therapeutic effect of Hydroxychloroquine on IgA Nephropathy course QUIgAN Study

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Study to Evaluate the Efficacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis (ELIXIR)

Sweden, Spain, Germany, Denmark, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

SGL-TX-GFR SGLT2i safety and efficacy on kidney allograft function in non-diabetic kidney transplant recipients: A randomized, double-blind, placebo controlled, national, multicenter trial.

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Esrd trials by city

Esrd in Toronto Esrd in Vancouver Esrd in Montreal Esrd in Calgary Esrd in Edmonton Esrd in Ottawa Esrd in Winnipeg Esrd in Quebec City Esrd in Hamilton Esrd in Kitchener Esrd in London Esrd in Halifax Esrd in New York Esrd in Los Angeles Esrd in Chicago Esrd in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease